---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000028"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-05-14T20:04:23+00:00"
generated_at: "2026-05-14T20:05:37.985971+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inhibrx Q1 2026 net loss $33.4M; cash $161.7M; ozekibart BLA submitted

## Summary
- Net loss $33.4M ($2.15/sh) vs $43.3M ($2.80/sh) YoY; R&D expense $25.2M down from $36.9M.
- Cash $161.7M at Mar 31, 2026 vs $124.2M at Dec 31, 2025; $75M loan amendment from Oxford.
- BLA submitted to FDA for ozekibart in conventional chondrosarcoma; discuss accelerated pathways for CRC and Ewing sarcoma.
- INBRX-106 Phase 2 HNSCC updated interim data in May 2026; PFS results expected Q4 2026.
- Debt increased to $175M; other expense $2.5M from higher interest on new $75M principal.

## SEC filing metadata
- accession: 0002007919-26-000028
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-05-14T20:04:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/0002007919-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/inhibrx-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000028
- JSON: https://secwatch.observer/filing/0002007919-26-000028.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000028.txt

## Key facts
- Earnings Releases
  Inhibrx Biosciences, Inc. reported the first quarter of 2026 results: net income $33.4 million, EPS $2.15 per share.
  - Period: the first quarter of 2026
  - Net income: $33.4 million
  - EPS: $2.15 per share
  - Result: reported results
  source text: Net loss was $33.4 million during the first quarter of 2026, or $2.15 per share, basic and diluted
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/0002007919-26-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.